Clinical value of serum JKAP in acute ischemic stroke patients

Abstract

Background Jun N‐terminal kinase pathway‐associated phosphatase (JKAP) regulates neuronal function, T helper (Th) 1/2/17 cell differentiation, and inflammatory process, but its clinical role in acute ischemic stroke (AIS) patients remains unclear. Hence, this study intended to evaluate JKAP level and its relationship with disease severity, Th1, 2, 17 secreted cytokines, adhesion molecules, and prognosis of AIS patients. Methods Serum JKAP of 122 AIS patients and 50 controls was detected by ELISA. For AIS patients only, Th1, 2, 17 secreted cytokines IFN‐γ, IL‐4, IL‐17; TNF‐α, ICAM‐1, and VCAM‐1 were also detected by ELISA. Results JKAP was decreased in AIS patients compared with controls (46.350 (interquartile range (IQR): 34.250–59.875) pg/ml vs. 84.500 (IQR: 63.175–113.275) pg/ml, p < 0.001), which could distinguish AIS patients from controls (area under curve (AUC): 0.810, 95% confidence interval (CI): 0.732–0.888). In AIS patients, JKAP negatively linked with the National Institutes of Health Stroke Scale (NIHSS) score (rs = −0.342, p < 0.001); besides, it was positively related to IL‐4 (rs = 0.213, p = 0.018) and negatively associated with IL‐17 (rs = −0.270, p = 0.003) but not related to IFN‐γ (rs = −0.146, p = 0.109). Furthermore, elevated JKAP associated with declined TNF‐α (rs = −0.219, p = 0.015) and ICAM‐1 (rs = −0.235, p = 0.009) but not related to VCAM‐1 (rs = −0.156, p = 0.085). Besides, declined JKAP was linked with 2‐year recurrence (p = 0.027) and 3‐year recurrence (p = 0.010) in AIS patients; while JKAP was not related to 1‐year recurrence or death risk (both p > 0.050). Conclusion JKAP may sever as a candidate prognostic biomarker in AIS patients, indicating its potency for AIS management.

JNK pathway‐associated phosphatase in acute ischemic stroke patients: Its correlation with T helper cells, clinical properties, and recurrence risk

“…Interestingly, a recent study reports JKAP possess the potency as a biomarker for AIS, while its sample size is relatively small, and it neither detects Th1 and Th17 cell percentage in blood, nor evaluates the RFS in AIS patients. 24 Therefore, our current study enrolled a relatively larger sample‐size AIS patients, evaluated their JKAP, Th1 and TH17 cells, then assess their correlation with RFS.…”

The longitudinal changes of serum JKAP and IL‐17A, and their linkage with anxiety, depression, and cognitive impairment in acute ischemic stroke patients

“… 13 , 14 , 15 , 16 Besides, a few studies also report the linkage of JKAP and IL‐17A with mental health in inflammation‐mediated and neurological disease patients. 13 , 17 , 18 , 19 , 20 , 21 For instance, JKAP is reversely linked with cognitive impairment progression in Alzheimer's disease patients. 18 In terms of IL‐17A, it is positively linked with anxiety, depression, and cognitive impairment in AIS patients.…”

“…Jun N‐terminal kinase (JNK) pathway‐associated phosphatase (JKAP), as a key JNK regulator, inactivates T‐cell receptor (TCR) signaling to involve in T‐cell mediated immunity, and suppresses Lck to reduce the secretion of interleukin (IL)‐17A, thereby participating in the pathology and progression of neurological diseases 13–16 . Besides, a few studies also report the linkage of JKAP and IL‐17A with mental health in inflammation‐mediated and neurological disease patients 13,17–21 . For instance, JKAP is reversely linked with cognitive impairment progression in Alzheimer's disease patients 18 .…”